Systemic blockade of TNF-α does not improve insulin resistance in humans. [electronic resource]
Producer: 20120229Description: 801-8 p. digitalISSN:- 1439-4286
- Adalimumab
- Adult
- Aged
- Anabolic Agents -- therapeutic use
- Anti-Inflammatory Agents, Non-Steroidal -- therapeutic use
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Arthritis, Rheumatoid -- drug therapy
- Cohort Studies
- Etanercept
- Female
- Follow-Up Studies
- Humans
- Immunoglobulin G -- therapeutic use
- Infliximab
- Insulin Resistance
- Male
- Metabolic Syndrome -- drug therapy
- Middle Aged
- Prospective Studies
- Psoriasis -- drug therapy
- Receptors, Tumor Necrosis Factor -- therapeutic use
- Reproducibility of Results
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.